I-Mab News

I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline

TipRanksApr 12 06:08 ET

I-MAB Analyst Ratings

BenzingaApr 12 06:03 ET

I-MAB Analyst Ratings

BenzingaMar 18 06:40 ET

Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)

TipRanksMar 18 06:20 ET

I-MAB Analyst Ratings

BenzingaMar 15 09:27 ET

I-MAB Buy Rating: Strategic Pivot to U.S. Market and Promising Pipeline

TipRanksFeb 12 08:18 ET

I-MAB Analyst Ratings

BenzingaFeb 8 15:10 ET

Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)

TipRanksFeb 8 15:10 ET

Needham Maintains Buy on I-MAB, Lowers Price Target to $23

BenzingaSep 25, 2023 05:57 ET

I-MAB Analyst Ratings

BenzingaSep 25, 2023 05:55 ET

Cantor Fitzgerald Reiterates Overweight on I-MAB, Maintains $25 Price Target

BenzingaSep 5, 2023 09:59 ET

I-MAB Analyst Ratings

BenzingaSep 5, 2023 09:58 ET

I-MAB Analyst Ratings

BenzingaAug 18, 2023 10:43 ET

I-MAB (IMAB) Gets a Buy From H.C. Wainwright

TipRanksAug 18, 2023 08:05 ET

I-MAB Analyst Ratings

BenzingaAug 18, 2023 04:17 ET

Needham Reiterates Buy on I-MAB, Maintains $24 Price Target

BenzingaJun 5, 2023 05:17 ET

Needham Reiterates Buy on I-MAB, Maintains $24 Price Target

BenzingaApr 19, 2023 07:02 ET

HC Wainwright Adjusts Price Target on I-Mab to $25 From $45, Maintains Buy Rating

MT NewswiresApr 3, 2023 08:22 ET

Analysts Offer Insights on Healthcare Companies: I-MAB (IMAB), Cerevel Therapeutics Holdings (CERE) and Shattuck Labs (STTK)

TipRanksApr 3, 2023 06:37 ET

HC Wainwright & Co. Maintains Buy on I-MAB, Lowers Price Target to $25

BenzingaApr 3, 2023 06:30 ET